Geneva, Switzerland, April 27, 2022 – 6:00 pm CEST GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), publishes its 2021 Universal Registration Document, in English, which has been filed on April 27, 2022 with the “Autorité des Marchés Financiers (AMF)”.
https://geneuro.ch/data/news/GeNeuro-PR-Mise-a-dispo-URD-2021-EN.pdf